Amphista Therapeutics Ltd. has released first data on its SMARCA2 program. The company conducted structurally guided discovery using high-resolution cryo-EM to deliver potent DCAF16-dependent Targeted Glues of SMARCA2, with exquisite selectivity over the closely related homologue SMARCA4.
When Robert Kennedy Jr. announced the cancellation of 22 projects related to mRNA vaccines and the end of new investments in that technology, the U.S. Secretary of Health only mentioned their use against respiratory viruses, without referring to other applications. The vaccines whose safety and effectiveness Kennedy is questioning are based on the same molecular principles as cancer vaccines under development. “Continued investment in mRNA technology is essential to fully realize its potential in oncology and ensure that promising strategies like neoantigen-based vaccines reach clinical application.” Kazuhiro Kakimi, professor at the Department of Immunology at Kindai University Faculty of Medicine, told BioWorld.
In its second deal with Novartis AG of the past 11 months, Monte Rosa Therapeutics Inc. is getting $120 million up front to collaborate on developing molecular glue degraders to treat immune-mediated diseases. The agreement could swell to $5.7 billion for Monte Rosa.
Tuojie Biotech (Shanghai) Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of neurological disorders, cardiovascular disorders, obesity, diabetes, chronic kidney diseases and diabetic nephropathy.
Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have divulged sphingosine 1-phosphate S1P3 receptor antagonists reported to be useful for the treatment of cancer, liver diseases, neurodegeneration, and metabolic, endocrine, cardiovascular and respiratory disorders.
Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has synthesized tricyclic heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Scientists at Gwangju Institute of Science & Technology and JD Bioscience Inc. have disclosed 5-HT2A receptor antagonists reported to be useful for the treatment of cancer, hyperlipidemia, obesity, diabetes, arteriosclerosis, hepatic steatosis, fibrosis and hypertension.
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplications and point mutations in the tyrosine kinase domain, are frequently observed in acute myeloid leukemia (AML) and contribute to disease progression and poor prognosis.
Auravax Therapeutics Inc. has received funding from the Gates Foundation to evaluate the efficacy of Nanosting-001 in validated swine models of influenza infection at Kansas State University College of Veterinary Medicine and The Pirbright Institute.
RSS
